Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
- C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF)
- Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty payments
- Nippon Shinyaku has been granted exclusive rights to and will be responsible for development of C21 in Japan
- Vicore retains rights to develop and commercialize C21 in all markets outside of Japan
Stockholm, February 9, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.
